Skip to content

Comparing the efficacy of Intravenous Paracetamol to Imtramuscular Pethidine for labour analgesia in ILorin: A randomized controlled study.

Comparing the efficacy of Intravenous Paracetamol to Imtramuscular Pethidine for labour analgesia in ILorin: A randomized controlled study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202308755450519
Enrollment
96
Registered
2023-08-07
Start date
2023-08-14
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Labour pain Relief

Interventions

Intravenous paracetamol infusion
Intramuscular pethidine

Sponsors

Self funded
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: INCLUSION CRITERIA Women with term gestation (37 to 42 weeks), with singleton fetus in cephalic presentation Women who present in active phase of labour (cervical dilatation of 4-6cm), either spontaneous or induced Consent to participate in the study.

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA Women with cervical dilatation of 7cm or more. Multiple gestation. Women with previous uterine surgery (caesarean section, myomectomy). Women with antepartum haemorrhage in index pregnancy. History of hyper-sensitivity to PCM and/or pethidine. Women with diagnosed liver disease and / or sickle cell disease patient.

Design outcomes

Primary

MeasureTime frame
Maternal labour pain score perception and satisfaction level with pain relief. Measured with VAS and Likert scale respectively

Secondary

MeasureTime frame
Maternal side effects (Nausea, vomiting, drowsiness, dyspnoea and hypotension) 2. Fetal heart rate abnormalities. 3. Duration of labour (drug –delivery interval) 4. Apgar score less than seven at five minutes and need for NICU admission 5. Need for anti-opioid (Naloxone).

Countries

Nigeria

Contacts

Public ContactNasiru IBRAHIM

Principal investigator

nasiruibrahim424@gmail.com+2347037957122

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026